Filing Details
- Accession Number:
- 0001179110-13-003191
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-02-20 19:16:59
- Reporting Period:
- 2013-02-15
- Filing Date:
- 2013-02-20
- Accepted Time:
- 2013-02-20 19:16:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1312622 | I Kaye Foster-Cheek | C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080 | Svp, Global Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-02-15 | 3,184 | $37.68 | 28,683 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-02-15 | 9,480 | $26.38 | 38,163 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-02-15 | 3,500 | $35.18 | 41,663 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-02-15 | 16,164 | $74.96 | 25,499 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to Buy) | Disposition | 2013-02-15 | 3,184 | $0.00 | 3,184 | $37.68 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2013-02-15 | 9,480 | $0.00 | 9,480 | $26.38 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2013-02-15 | 3,500 | $0.00 | 3,500 | $35.18 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,241 | 2022-03-29 | No | 4 | M | Direct | |
| 42,312 | 2020-09-30 | No | 4 | M | Direct | |
| 15,167 | 2021-03-31 | No | 4 | M | Direct |
Footnotes
- The shares were sold pursuant to a 10b5-1 plan.
- 12.5% of the shares subject to the option became exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
- Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and become exercisable at a rate of 1/48th per month thereafter.
- The shares were sold at prices ranging from $74.90 to $75.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold to each separate price.
Billionaire Hedge Funds
